Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
November 6, 2025
- Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
- Tepid Exchanges at Chuikyo over Public-Private Working Group Report
November 6, 2025
- Takaichi Pledges Balanced Approach to Drug Pricing, Off-Year Revisions
November 6, 2025
- Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
November 5, 2025
- MHLW Clarifies When Generic Drug Mergers Must Be Reviewed by Antitrust Regulator
November 5, 2025
- LDP Project Team Urges Economic Measures Reflecting Price Pressures
November 4, 2025
- Former Flagship Brands among 506 Drugs Set for Delisting
November 4, 2025
- Anticoagulants and Other Drugs under PMDA Safety Review
November 4, 2025
- Health Minister Vows to Balance Public Burden, Innovation, and Supply in FY2026 Revision
October 31, 2025
- LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
- Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
- Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
October 30, 2025
- Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
October 30, 2025
- Japan to Delist 506 Drugs from NHI Price List, Including Category A Products and LLPs
October 30, 2025
- Exclude High-Price-Gap Products from Unprofitable Drug Re-Pricing: Chuikyo
October 30, 2025
- FIRM Urges Continued Premiums for Conditionally Approved Regenerative Medicines
October 30, 2025
- Japan Eyes Review of Generic Price Bands, Brand-Based Revisions for Tier A Products
October 30, 2025
- Japan PM Warns of Overreliance on China for Pharmaceutical Ingredients
October 29, 2025
- Public-Private WG’s Discussion Summary Focuses on Drug Pricing, Raises MFN Risk
October 29, 2025
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…